Amgen (AMGN) : Naples Global Advisors reduced its stake in Amgen by 0.78% during the most recent quarter end. The investment management company now holds a total of 15,920 shares of Amgen which is valued at $2,555,478 after selling 125 shares in Amgen , the firm said in a disclosure report filed with the SEC on Jul 13, 2016.Amgen makes up approximately 1.03% of Naples Global Advisors’s portfolio.
Other Hedge Funds, Including , Gofen Glossberg Il boosted its stake in AMGN in the latest quarter, The investment management firm added 3 additional shares and now holds a total of 21,117 shares of Amgen which is valued at $3,389,701. Amgen makes up approx 0.14% of Gofen Glossberg Il’s portfolio.Quotient Investors reduced its stake in AMGN by selling 5,050 shares or 52.37% in the most recent quarter. The Hedge Fund company now holds 4,593 shares of AMGN which is valued at $737,268. Amgen makes up approx 0.34% of Quotient Investors’s portfolio.Chevy Chase Trust Holdings boosted its stake in AMGN in the latest quarter, The investment management firm added 215 additional shares and now holds a total of 677,575 shares of Amgen which is valued at $109,157,333. Amgen makes up approx 0.60% of Chevy Chase Trust Holdings’s portfolio.Next Financial Group Inc boosted its stake in AMGN in the latest quarter, The investment management firm added 15 additional shares and now holds a total of 2,118 shares of Amgen which is valued at $341,210. Amgen makes up approx 0.11% of Next Financial Group Inc’s portfolio.Nadler Financial Group boosted its stake in AMGN in the latest quarter, The investment management firm added 6 additional shares and now holds a total of 2,111 shares of Amgen which is valued at $340,082. Amgen makes up approx 0.14% of Nadler Financial Group’s portfolio.
Amgen closed down -0.35 points or -0.21% at $162.93 with 18,15,610 shares getting traded on Monday. Post opening the session at $163.82, the shares hit an intraday low of $162.79 and an intraday high of $164 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Amgen reported $2.90 EPS for the quarter, beating the analyst consensus estimate by $ 0.29 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $2.61. The company had revenue of $5527.00 million for the quarter, compared to analysts expectations of $5321.84 million. The company’s revenue was up 9.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.48 EPS.
Many Wall Street Analysts have commented on Amgen. Amgen was Initiated by Bernstein to “Mkt Perform” on Jun 29, 2016.
Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.